Sirdalud 2-4-6 mg drug. Indications for use, instructions, price, reviews

In the complex drug therapy of joint diseases and autoimmune pathologies that cause muscle spasms, include Sirdalud at a dosage of 2, 4 or 6 mg. The drug belongs to the category of muscle relaxants of central (systemic) action. The instructions for use recommend taking the medicine to patients with myopathy.

Composition and form of release

Systemic muscle relaxant Turkish manufacturer pharmaceutical company Novartis produces in the form of white tablets of medium size flat-cylindrical shape. Each 2 mg drug unit has beveled edges and a dividing line in the middle for reduced dosage administration.

Sirdalud with an active ingredient concentration of 4 and 6 mg on the front surface contains intersecting grooves that allow the tablet to be divided into 4 parts. The Turkish muscle relaxant is delivered to pharmacies in sealed blisters made of aluminum foil and transparent medical polymer.

Sirdalud 2 mg (indications for use include the use in maintenance therapy of chronic systemic pathologies of autoimmune genesis) contains OZ engraving on the back surface. The RL bigram is applied to the tablets with a dosage of 4 mg.

Secondary packaging - a pack of smooth laminated cardboard with a clear print.

It contains the following information:

• name of the drug;
• manufacturer's name;
• the number of tablets;
• dosage of one unit of a medicinal product

Each pack contains 3 blisters of 10 tablets. The pharmacologically active substance of Sirdaluda is tizanidine in the form of hydrochloride. The chemical blocks polysynaptic reflexes in the spinal cord, resulting in an antispastic effect.

Auxiliary components of a muscle relaxant drug are presented in the table:

Substance	Properties
Milk sugar monohydrate	Natural preservative that prolongs the shelf life of the tablets. Monohydrogenated lactose serves as a breeding ground for beneficial intestinal microflora. The substance has a low hygroscopicity and does not change its properties under the influence of humid or acidic environments.
Stearic acid	Refractory lipid compound, which is used in medicines as a stabilizer of a multicomponent system and a structurant
Microcrystalline cellulose	A source of dietary fiber with sorbing properties. It is used in tablets to stabilize, emulsify, and shape the drug.
Dehydrated colloidal silicon dioxide	Natural enterosorbent that suppresses acute gastrointestinal infections, eliminating allergic reactions provoked by intoxication.

The auxiliary content of the Turkish-made systemic muscle relaxant is biochemically neutral and does not cause side effects or a sharp immune response.

Pharmacological properties

The active substance of the drug relaxes muscle fibers by direct physiological influence on the innervation structures of the spinal cord. Tizanidine hydrochloride inhibits the release of neurotransmitters in the synaptic space.

This effect leads to the elimination of muscle spasms by slowing down nerve excitation in the target fibers. Muscle tone, provoked by an excessive concentration of neurotransmitters, temporarily disappears.

As a result, the functions of the structures affected by the pathology are fully restored or partially improved. Sirdalud is effective in the spasmodic state of the striated muscles.

The pharmacological properties of the drug combine a pronounced muscle relaxant effect with a moderate analgesic effect. Muscle spasms often cause compression irritation of the pain receptors.

Pathological symptoms are characterized by paroxysms of varying intensity and duration. Tizanidine hydrochloride is an effective skeletal muscle relaxant.

The substance suppresses muscle rigidity, characterized by loss of elasticity and stubbornness of spasmodic fibers. The relaxing effect of the drug is aimed at stimulating presynaptic adrenorecetors.

The pharmacological properties of Sirdalud are based on the ability of the active ingredient to suppress the release of neurotransmitter amino acids. As a result, the excitation of intermediate neurons decreases, the functional disorders of which play a leading role in the mechanism of the formation of muscle spasm.

Pharmacodynamics and pharmacokinetics

Sirdalud 2-4-6 mg (indications for use are positioned as a systemic muscle relaxant) is aimed at inhibiting amino acid compounds activating NMDA receptors.

Anatomical structures are ligand-dependent ionotropic transmembrane proteins located in the nerve canals that conduct electrochemical impulses.

Their inhibition by tizanidine hydrochloride slows down or completely stops polysynaptic signaling in the spinal cord. The effectiveness of the drug has been clinically proven for muscle hypertonia of cerebral genesis.

Such pathological manifestations of systemic diseases accompany acute pain reactions. Sirdalud reduces the likelihood of seizure conditions of the clonic type, minimizes spastic symptoms.

Tizanidine hydrochloride is absorbed into the systemic circulation in the full amount of the dose taken. The maximum concentration in the plasma fraction is reached after 45-60 minutes. after oral administration of the drug.

The bioavailability of the active substance is 34%. The maximum saturation of blood plasma with tizanidine hydrochloride is 12.3 and 15.6 ng / ml after a single use and with a course intake, respectively, at a dosage of 4 mg.

The physiologically active component binds to protein particles in the blood by about 30%. The systemic muscle relaxant is metabolized by the hepatobiliary organ by 95%.

The main role in the process of biotransformation of hydrochloride is played by the isoenzyme CYP1A2, which is attributed to the cytochrome mechanism of P₄₅₀. Sirdalud metabolites do not possess physiologically significant activity.

The half-life of tizanidine hydrochloride is 2-4 hours. About 70% of the orally taken volume of the drug is removed from the body during the deurination process. No more than 4.5% are evacuated unchanged.

There was no pharmacokinetic dependence of the use of the drug during, before and after meals. An increase in the concentration of the active substance in the plasma fraction of blood by 1/3 when taking the drug simultaneously with food has no significant clinical significance.

When using Sirdalud in a daily dosage of 1-20 mg, the drug has linear pharmacodynamics. In patients with renal dysfunction with creatinine clearance less than 25 ml / min. the concentration of tizanidine hydrochloride in blood plasma is doubled.

Indications for use

Sirdalud is prescribed for a spastic state of skeletal muscles of any etiology.

Systemic muscle relaxant is used for:

• Cervical or lumbar dorsopathy. Musculoskeletal pathology is associated with limited mobility, partial loss of tactile sensitivity, and vascular-trophic disorders.
• Chronic inflammation of the spinal column, progressive course.
• Intercostal neuralgia. Pain syndrome causes compression irritation of peripheral nerve fibers.
• Myelopathy. Injury to the spinal cord, mechanical, inflammatory, chemical, or infectious, combines painful reactions with muscle spasms.
• Multiple sclerosis. Chronic autoimmune disease with destruction of the myelin sheath of the spinal and cerebral nerves characterizes the constant spastic state of the muscular structures of the limbs and spine.
• Central paralysis or limited paresis. Musculoskeletal disorders provoked by damage to the peripheral nervous system are symptomatically treated with Sirdalud.
• Muscle spasms of epileptic, viral or bacterial origin.

  

Sirdalud is used in the complex therapy of static and functional pathologies of the spinal column, individual sections of the skeletal frame. The drug does not have teratogenic activity, therefore it is indicated at any stage of pregnancy, during breastfeeding.

Tizanidine hydrochloride does not cross the hematoplacental barrier, does not penetrate into breast milk. Sirdalud is prescribed after surgery to remove hernial protrusion of the intervertebral discs, with osteoarthritis of the hip joint.

The drug is considered an effective means of relieving spastic symptoms in severe neurological or neuroendocrine pathologies, traumatic spinal injuries.

Sirdalud at a dosage of 2 mg is prescribed as part of continuous maintenance therapy for patients with multiple sclerosis and other incurable autoimmune diseases. Instructions for use indicate the ability of tizanidine to relieve painful symptoms and muscle tension in sciatica.

Contraindications

In the reviews, patients note the safety of Sirdalud in comparison with analogues. Turkish systemic muscle relaxant has a minimum number of absolute contraindications.

The drug is prohibited to use for the treatment of patients with:

• diagnosed with anaphylaxis to tizanidine hydrochloride;
• individual biological lactose intolerance;
• cirrhosis;
• severe hepatobiliary disorders caused by acute intoxication or hepatitis;

There is no scientific data on the effect of Sirdalud on the body of children and adolescents. Such studies have not been conducted. Treatment with the drug in minor patients is not recommended.

Method of administration and dosage

A systemic muscle relaxant has a narrow therapeutic range index, reflecting the breadth of safe drug action. The indicator is the ratio of the lethal dose to the clinically effective dose.

Sirdalud is characterized by a significant injection of tizanidine hydrochloride into the plasma fraction of blood and the variability of the therapeutic effect. The dosage and frequency of use are selected individually, taking into account the biological tolerance, anamnesis, the characteristics of the course of the pathological process.

The drug is taken by mouth. The tablet is not chewed or crushed in any other way, swallowing whole and drinking plenty of water. The initial daily dose is set at 3 units of the drug with an active ingredient concentration of 2 mg.

With myopathic syndromes

Chronic progressive muscle disease is characterized by regular painful paroxysms in combination with spasms of elastic fibers and limitation of body mobility. In the symptomatic therapy of myopathies, Sirdalud is used in the amount of 2 or 4 mg 3 times a day.

For severe or prolonged muscle cramps, you can take an extra tablet at bedtime. For maintenance therapy during the period of remission in chronic myopathy, the drug is prescribed in a reduced dosage. The tablet is divided into 2 or 4 parts while maintaining the frequency of use.

For neurological spasms of skeletal muscles

The starting daily dose at the beginning of treatment does not exceed 6 mg, divided into 3 doses at equal time intervals. The consumed volume of the drug is gradually increased according to the prescription of a neurologist.

The standard therapy regimen involves increasing the dose by 2-4 mg per day every 3-4 days. The course of treatment is 10-12 days. Then they take a week break. The maximum clinical effect in muscle spasms caused by neurological syndromes is observed after taking 12-24 mg of Sirdalud per day.

In old age

The experience of treating this category of patients with systemic muscle relaxant is limited. Persons over 65 are advised to start taking Sirdalud at a dosage of 2 mg 3 times a day under the supervision of a neurologist. The volume of the drug can be increased if clinically necessary and well tolerated by the patient up to 24 mg per day.

With impaired renal function

Treatment of patients with severe nephrotic disorders begins with a dosage of 2 mg once a day. The volume is increased carefully, taking into account the observed clinical effect and tolerability. To obtain a pronounced improvement in the dynamics of the disease, the frequency of administration is increased, and not a single dose.

With functional disorders of the liver

Severe disorders in the work of the hepatobiliary mechanism, intoxication and viral lesions are among the contraindications to the appointment of Sirdalud. The use of the drug is possible in the absence of an approved analogue under the supervision of a physician in the minimum clinically appropriate doses.

Side effects

Sirdalud 2-4-6 mg (indications for use characterize the drug as having several rarely occurring side effects), patients tolerate mostly well.

Rarely, the digestive system reacts to the penetration of tizanidine hydrochloride with gastrointestinal disorders, drying out of the mucous membranes of the oral cavity, short-term nausea urges.

In some patients, while taking Sirdalud, blood pressure decreases, heartbeat slows down. These side effects are short-lived. In elderly patients, dizziness and sleep disturbance may occur.

Sometimes, with a long course of taking the drug, myasthenic states develop - episodic weakness or rapid muscle fatigue. When treating with Sirdalud, it is possible to change laboratory parameters with increased activity of liver enzymes.

It is recommended to stop taking the drug 3 days before the blood test. The use of Sirdalud within the specified therapeutic range usually does not cause side effects.

Reception of a systemic muscle relaxant in high doses for the symptomatic treatment of chronic spasmodic conditions leads to some negative reactions. However, severe side effects that require discontinuation of the drug do not occur.

Overdose

Intoxication of the body with tizanidine hydrochloride occurs with regular or single intake of a muscle relaxant in a daily volume exceeding 36 mg.

Overdose is manifested:

• a sharp drop in intravascular pressure;
• slow heartbeat with the prospect of loss of consciousness;
• pathological drowsiness;
• severe dizziness;
• activation of the gag reflex;
• nervous excitement;
• constriction of the pupils and impaired refraction;
• shortness of breath.

To eliminate such conditions, enterosorbents are taken. To remove excess tizanidine hydrochloride, diuretic drugs are used to force urination.

After removal of the substance from the body, symptomatic therapy is carried out, aimed at stabilizing the physiological parameters. In clinical practice, a case of a single dose of the drug in the amount of 400 mg is known.

Complete recovery of the patient was noted without consequences and negative features. Cases of death with a significant overdose of Sirdalud have not been recorded.

special instructions

Hypotensive conditions are possible with long-term administration of the drug in a daily volume of more than 24 mg. In patients with clinical manifestations of renal dysfunction, it is recommended to monitor the condition of the organ throughout the entire course of treatment using laboratory methods and ultrasound diagnostics.

Sirdalud 4-6 mg (indications for use are not recommended for use for a course of treatment with severe or complicated other metabolic disorders, glucose-galactose malabsorption syndrome) can cause drowsiness. It is not recommended to drive vehicles and hazardous industrial machinery during the treatment period or installations, perform high-altitude work or critical operations requiring maximum concentration attention.

In higher doses, Sirdalud provokes an acceleration of psychomotor reactions. A decrease in the bioavailability of the active substance was observed in patients who smoke 10 or more cigarettes daily. With prolonged course of treatment, they need to increase the dose.

Drug interactions

It is undesirable to combine a muscle relaxant with antihypertensive drugs, inhibitors of the cytochrome enzyme CYP1A2. Their combined use increases the concentration of tizanidine hydrochloride in blood plasma, which can lead to symptoms of drug intoxication.

It is forbidden to combine Sirdalud with:

• Tsimedin - a blocker of H2-receptors of histamine;
• Rofecoxib - a non-steroidal anti-inflammatory drug used to treat osteoarthritis, dysmenorrhea, acute pain syndrome of various etiogenesis;
• Tiklopedin - an antiplatelet drug that slows down platelet adhesion;
• Propafenone and other antiarrhythmic pills;
• hormonal-based oral contraceptives;
• fluoroquinolone antibiotics.

Such drug combinations cause cardiac dysfunction with prolongation of the QTc interval. WITH caution combine Sirdalud with Azithromycin, Amitriptyline, Cisapride due to a similar negative effect.

Cross-use of a systemic muscle relaxant with antihypertensive drugs leads to a pronounced decrease in blood pressure and bradycardic symptoms.

The combination of Sirdalud with Rifampicin reduces the concentration of tizanidine hydrochloride in the plasma fraction of the blood, which worsens the clinical effect of the drug.

The medicine is not compatible with alcoholic beverages. Combining tizanidine with ethanol increases the likelihood of side effects. Sirdalud enhances the depressing effect of alcohols on the central nervous system.

Inhibitors of histamine receptors, hypnotics and sedatives increase the drowsiness characteristic of the Turkish muscle relaxant. Antagonists of α2 adrenergic receptors are potentially capable of enhancing hypotensive manifestations.

Analogs

Sirdalud can be replaced with Tizalud or Midocalm. The first acts as an almost complete analogue of the drug in question in terms of the component base and dosage form.

Mydocalm is a centrally acting muscle relaxant based on tolperisone. The medicine is produced in the form of tablets in an enteric film shell and in the form of a solution for injection.

Terms of sale and storage, prices

Sirdalud is a prescription drug. In pharmacies, tablets are dispensed upon presentation of the corresponding form filled out by the doctor in accordance with the current rules. The price of a pack of the drug is 250-300 rubles.

The instruction for use recommends storing the medicine that relieves pain syndromes and eliminates muscle spasms at a maximum temperature of + 25 ° C. The shelf life of Sirdalud 2-4-6 mg is 60 months.

Video about the drug Sirdalud

Sirdalud instructions for the use of tablets: